Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia

by

Fulfills important regulatory milestone for AP-SA02 on the path toward a future BLA and supports expansion into pediatric patients LOS ANGELES, July 13, 2026 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a late clinical-stage biotechnology…

Source: prnewswire

Country: United States